J. Ring
doi : 10.1111/jdv.17605
Volume 35, Issue 10 p. 1916-1916
K. Brockow
doi : 10.1111/jdv.17563
Volume 35, Issue 10 p. 1917-1918
F. Poot
doi : 10.1111/jdv.17600
Volume 35, Issue 10 p. 1919-1920
S. Walsh
doi : 10.1111/jdv.17535
Volume 35, Issue 10 p. 1921-1921
F.M. Camacho Martinez
doi : 10.1111/jdv.17602
Volume 35, Issue 10 p. 1922-1925
E. Schmidt,H. Rashid,A.V. Marzano,A. Lamberts,G. Di Zenzo,G.F.H. Diercks,S. Alberti-Violetti,R.J. Barry,L. Borradori,M. Caproni,B. Carey,M. Carrozzo,G. Cianchini,A. Corrà,F.G. Dikkers,C. Feliciani,G. Geerling,G. Genovese,M. Hertl,P. Joly,J.M. Meijer,V. Mercadante,D.F. Murrell,M. Ormond,H.H. Pas,A. Patsatsi,S. Rauz,B.D. van Rhijn,M. Roth,J. Setterfield,D. Zillikens,C.Prost,G. Zambruno,B. Horváth,F. Caux
doi : 10.1111/jdv.17395
Volume 35, Issue 10 p. 1926-1948
This guideline has been initiated by the task force Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology, including physicians from all relevant disciplines and patient organizations. It is a S3 consensus-based guideline that systematically reviewed the literature on mucous membrane pemphigoid (MMP) in the MEDLINE and EMBASE databases until June 2019, with no limitations on language. While the first part of this guideline addressed methodology, as well as epidemiology, terminology, aetiology, clinical presentation and outcome measures in MMP, the second part presents the diagnostics and management of MMP. MMP should be suspected in cases with predominant mucosal lesions. Direct immunofluorescence microscopy to detect tissue-bound IgG, IgA and/or complement C3, combined with serological testing for circulating autoantibodies are recommended. In most patients, serum autoantibodies are present only in low levels and in variable proportions, depending on the clinical sites involved. Circulating autoantibodies are determined by indirect IF assays using tissue substrates, or ELISA using different recombinant forms of the target antigens or immunoblotting using different substrates. The major target antigen in MMP is type XVII collagen (BP180), although in 10–25% of patients laminin 332 is recognized. In 25–30% of MMP patients with anti-laminin 332 reactivity, malignancies have been associated. As first-line treatment of mild/moderate MMP, dapsone, methotrexate or tetracyclines and/or topical corticosteroids are recommended. For severe MMP, dapsone and oral or intravenous cyclophosphamide and/or oral corticosteroids are recommended as first-line regimens. Additional recommendations are given, tailored to treatment of single-site MMP such as oral, ocular, laryngeal, oesophageal and genital MMP, as well as the diagnosis of ocular MMP. Treatment recommendations are limited by the complete lack of high-quality randomized controlled trials.
J.J. Grob,A. Guminski,J. Malvehy,N. Basset-seguin,B. Bertrand,P. Fernandez-Penas,R. Kaufmann,I. Zalaudek,C. Gaudy-Marqueste,M.C. Fargnoli,L. Tagliaferri,B. Fertil,V. Del Marmol,A. Stratigos,C. Garbe,K. Peris
doi : 10.1111/jdv.17466
Volume 35, Issue 10 p. 1949-1956
No simple classification system has emerged for ‘advanced basal cell carcinomas’, and more generally for all difficult-to-treat BCCs (DTT-BCCs), due to the heterogeneity of situations, TNM inappropriateness to BCCs, and different approaches of different specialists.
A. Balato,E. Scala,F. Ayala,A. Bauer,M.-N. Crépy,M. Gonçalo,J. Duus Johansen,S.M. John,T. Rustemeyer,N. Wagner,M. Wilkinson,A. Giménez-Arnau
doi : 10.1111/jdv.17483
Volume 35, Issue 10 p. 1957-1962
To our knowledge, an international consensus is lacking regarding the development of an adequate informed consent form for a patch test (PT) and the information that should be included in such document.
T. Passeron,C.C. Zouboulis,J. Tan,M.L. Andersen,R. Katta,X. Lyu,L. Aguilar,D. Kerob,A. Morita,J. Krutmann,E.M.J. Peters
doi : 10.1111/jdv.17432
Volume 35, Issue 10 p. 1963-1975
Exposome factors that lead to stressed skin can be defined as any disturbance to homeostasis from environmental (meteorological factors, solar radiation, pollution or tobacco smoke) and/or internal exposure (unhealthy diet, hormonal variations, lack of sleep, psychosocial stress). The clinical and biological impact of chronic exposome effects on skin functions has been extensively reviewed, whereas there is a paucity of information on the impact of short-term acute exposure. Acute stress, which would typically last minutes to hours (and generally no more than a week), provokes a transient but robust neuroendocrine-immune and tissue remodelling response in the skin and can alter the skin barrier. Firstly, we provide an overview of the biological effects of various acute stressors on six key skin functions, namely the skin physical barrier, pigmentation, defences (antioxidant, immune cell-mediated, microbial and microbiome maintenance), structure (extracellular matrix and appendages), neuroendocrine and thermoregulation functions. Secondly, we describe the biological and clinical effects on adult skin from individual exposome factors that elicit an acute stress response and their consequences in skin health maintenance. Clinical manifestations of acutely stressed skin may include dry skin that might accentuate fine lines, oily skin, sensitive skin, pruritus, erythema, pale skin, sweating, oedema and flares of inflammatory skin conditions such as acne, rosacea, atopic dermatitis, pigmentation disorders and skin superinfection such as viral reactivation. Acute stresses can also induce scalp sensitivity, telogen effluvium and worsen alopecia.
P. Lau,M. Shen,F. Ma,Y. Chen,J. Zhang,J. Su,X. Chen,H. Liu
doi : 10.1111/jdv.17437
Volume 35, Issue 10 p. 1976-1986
Several approaches to active immunotherapy for melanoma, including peptide-based vaccines (PVs), autologous tumour cell vaccines (TCVs), allogeneic TCVs and autologous dendritic cell vaccines (DCVs), have been investigated in clinical trials. However, comprehensive evidence comparing these interventions remains unavailable. The objective of this study was to expand previous work to compare and rank the immunotherapeutic strategies for melanoma in terms of overall survival and toxic effects with a Bayesian network meta-analysis. Methodologically, we performed a network meta-analysis of head-to-head randomized controlled trials comparing and ranking cancer vaccine approaches for patients with melanoma. PubMed, MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, the WHO International Clinical Trials Registry Platform and ClinicalTrials.gov were searched up to 31 July 2020. We estimated summary hazard ratios for death and risk ratios for toxicity. The effects of the underlying prognostic variable on survival benefits were examined by meta-regression. We performed subgroup analysis for the outcomes based on metastatic categories. Overall, we identified 4776 citations, of which 15 head-to-head randomized controlled trials (3162 participants) were included in the analysis. In terms of efficacy, allogeneic tumour cell vaccines plus immunotherapy adjuvants, peptide-based vaccines plus immunotherapy adjuvants and standard therapy were more effective than peptide vaccines. The proportion of women was inversely associated with mortality risk. For safety, all treatments were inferior to allogeneic tumour cell vaccines except for allogeneic tumour cell vaccines plus chemotherapy. Peptide vaccines plus immunotherapy adjuvants led to an increased risk of adverse events compared to allogeneic tumour cell vaccines plus immunotherapy adjuvants. These results suggest that allogeneic TCV and autologous DCV are better than standard therapy. PV plus immune modulators are the most effective strategy among all comparable strategies but is associated with increased toxicity. Any combination regimens for cancer therapeutic vaccines need to be balanced between risk and benefit profiles.
B.L. Stuart,L. Howells,R.L. Pattinson,J.R. Chalmers,D. Grindlay,N.K. Rogers,E. Grinich,T. Pawlitschek,E.L. Simpson,K.S. Thomas
doi : 10.1111/jdv.17335
Volume 35, Issue 10 p. 1987-1993
Atopic eczema (herein referred to as ‘eczema’) is a skin disease characterized by remitting and relapsing symptoms. The Harmonising Outcome Measures for Eczema (HOME) initiative was developed to establish a core outcome set (COS) for eczema to be measured for all future eczema trials. The core outcome set for atopic eczema clinical trials includes the domain for patient-reported eczema control, but a review of the validation of available eczema control instruments was lacking. We aimed to review the literature and systematically assess the measurement properties of validated patient-reported outcome instruments that capture eczema control. PubMed and Ovid EMBASE were searched up to 24 January 2020 for any study that reported on PROM instrument development or validation. The COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) criteria were used to assess the quality of eligible studies. We screened 12 036 titles and abstracts and 58 full texts. A total of 12 papers were included, reporting on seven PROMS. These were assessed with respect to development, reliability, construct validity and responsiveness. Two instruments, Recap of Atopic Eczema (RECAP) and the Atopic Dermatitis Control Tool (ADCT), have been developed and validated to a sufficient standard to support their recommendation as patient-reported outcome instruments for measuring control of atopic eczema as part of the HOME Core Outcome Set.
T. Montero-Vilchez,C. Cuenca-Barrales,A. Martinez-Lopez,A. Molina-Leyva,S. Arias-Santiago
doi : 10.1111/jdv.17436
Volume 35, Issue 10 p. 1994-2006
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global pandemic that has spread all over the word. To avoid the virus transmission, healthcare workers must wear adequate personal protective equipment (PPE). PPE is associated with several side events, including skin reactions. The objective of this study was to summarize the prevalence, type and risk factors for cutaneous adverse events related to PPE and prevention measures to avoid them. A systematic review and meta-analysis was conducted using MEDLINE, Scopus and EMBASE databases from conception to 21 January 2021. All types of epidemiological studies regarding skin adverse events related to PPE were included. The literature search identified 1007 references, 35 of them met the eligible criteria and were included for analysis, representing 31 453 participants. The media of skin side events related to PPE was 75.13%. The rate of cutaneous adverse events related to mask was 57.71%, and those associated with gloves and hand hygiene products was 49.16%. Most common skin adverse events were contact dermatitis, acne and itching. The most damaged anatomical regions were the nasal bridge, the cheeks and the hands. The duration of PPE wearing was the most common risk factor. Frequent handwashing, gloves and masks were the agents most frequently related to skin reactions. N95 respirators were the most harmful mask type for the skin. Hydrocolloid use prevented from developing skin adverse events related to masks. In conclusion, the rate of cutaneous adverse events related to PPE use is high. A longer duration of PPE wearing was the most common risk factor. Using hydrocolloid could prevent from skin injuries related to mask use.
M. Marques-Silva,C. Lisboa,N. Gomes,A.G. Rodrigues
doi : 10.1111/jdv.17461
Volume 35, Issue 10 p. 2007-2021
In the late 90s, a sharp increase of treatment failures of Trichomonas vaginalis (TV) infections with metronidazole (MTZ) was reported, representing a problem due to limited treatment options. We proposed to review the available evidence on the frequency of MTZ resistance by TV isolates and the relationship between treatment failure and in vitro resistance to MTZ. A systematic review based on the PRISMA guidelines was conducted by searching published studies in three different databases (PubMed, Scopus and Web of Science) up to December 2020. The extracted studies were uploaded to Covidence software; screening was guided based on inclusion and exclusion criteria. Additionally, different articles were included through other sources. For each article, study design, objectives, study population and key outcomes were summarized. We found 403 references from the databases and four extra studies. After duplicate removal and screening of title, abstract and full text, 27 studies were included. The selected studies were published between 1983 and 2019; all except one addressed only vaginal TV infection. We identified four major populations in vitro MTZ resistance: two studies evaluated female adolescents; other two assessed HIV-positive women. Fifteen studies considered MTZ resistance in newly diagnosed vaginal TV infection. Finally, eight articles studied in vitro susceptibility of isolates from women with clinical resistant trichomoniasis. High level of in vitro MTZ resistance was rare; low-moderate level was described in most of the cases. Although clinical resistance to MTZ of trichomoniasis was widely reported, there was a paucity of prospective controlled studies. Our review unveiled the need to standardize susceptibility testing, to define breakpoints for detection of MTZ-resistant isolates and to correlate with clinical outcome. It is important to establish criteria to define clinical resistance to MTZ. Such a consensus would foster the development of surveillance studies about clinical and microbiological response to MTZ treatment.
P. Weber,C. Sinz,C. Rinner,H. Kittler,P. Tschandl
doi : 10.1111/jdv.17464
Volume 35, Issue 10 p. 2022-2026
Chronic sun damage in the background is common in pigmented actinic keratoses and Bowen’s disease (pAK/BD). While explainable artificial intelligence (AI) demonstrated increased background attention for pAK/BD, humans frequently miss this clue in dermatoscopic images because they tend to focus on the lesion.
U. Mrowietz,T. Dieckmann,S. Gerdes,S. Szymczak,R. von Spreckelsen,A. Körber
doi : 10.1111/jdv.17434
Volume 35, Issue 10 p. 2027-2033
Assessment of psoriasis is exclusively done measuring severity using somatic scores such as the psoriasis area and severity index or patient-reported outcomes such as the dermatology life quality index. There is no established tool to measure a patient's individual psoriasis activity over time.
K. Reich,J.B. Hansen,L. Puig,M.P. Konstantinou,R.B. Warren
doi : 10.1111/jdv.17433
Volume 35, Issue 10 p. 2034-2044
The pathway for treatment of psoriasis is partly dependent upon disease severity, and patients may experience inadequate response at any point along the treatment pathway. Patients who repeatedly fail therapy represent a population in whom effective and well-tolerated treatment options are limited.
D. Wilsmann-Theis,C. Kromer,S. Gerdes,C. Linker,N. Magnolo,R. Sabat,K. Reich,R. Mössner
doi : 10.1111/jdv.17441
Volume 35, Issue 10 p. 2045-2050
Palmoplantar pustulosis (PPP) is a chronic skin disease with painful erythematous scaly or crusty lesions and pustules on the palms and soles. Apremilast is a phosphodiesterase 4 inhibitor that has proven effective in the therapy of psoriasis, psoriatic arthritis and in oral ulcers associated with Behcet’s disease.
L. Giraud-Kerleroux,N. Bellon,A. Welfringer-Morin,S. Leclerc-Mercier,I. Costedoat,J. Coquin,A. Brun,A.-M. Roguedas-Contios,C. Bernier,B. Milpied,F. Tétart,A. Du Thanh,N. Cordel,B. Bensaid,C. Fargeas,M. Tauber,S. Renolleau,F. Boralevi,S. Ingen-Housz-Oro,C. Bodemer
doi : 10.1111/jdv.17469
Volume 35, Issue 10 p. 2051-2058
The distinction between epidermal necrolysis [EN; including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and overlap syndrome] and erythema multiforme major (EMM) in children is confusing. We aimed to better describe and compare these entities.
T. Kogame,T. Kamitani,H. Yamazaki,Y. Ogawa,S. Fukuhara,K. Kabashima,Y. Yamamoto
doi : 10.1111/jdv.17443
Volume 35, Issue 10 p. 2059-2066
Although polypharmacy is known to cause side-effects due to drug–drug interactions, dermatological symptoms triggered by polypharmacy are not fully addressed.
S. Ständer,C.M. Hammers,A. Vorobyev,E. Schmidt,J.E. Hundt,C.D. Sadik,T. Lange,D. Zillikens,R.J. Ludwig,K. Kridin
doi : 10.1111/jdv.17304
Volume 35, Issue 10 p. 2067-2073
While clustering of bullous pemphigoid (BP) with neuropsychiatric diseases is well-established, the clinical and immunological profile of BP patients with this comorbidity remains to be decisively determined.
K. Kridin,F. Hübner,A. Recke,R. Linder,E. Schmidt
doi : 10.1111/jdv.17465
Volume 35, Issue 10 p. 2074-2078
Apart from bullous pemphigoid (BP), the association of other autoimmune bullous diseases (AIBDs) with neurological conditions is poorly understood.
A. Torrelo,L. Vergara-de-la-Campa,J.M. Azaña,S. Greenberger,J.M. Lam,L.P. Lawley,M.-A. Morren,J.V. Schaffer,I. García-Doval,A. Matito,I. Alvarez-Twose
doi : 10.1111/jdv.17345
Volume 35, Issue 10 p. 2079-2084
Maculopapular cutaneous mastocytosis (MPCM) in children is classified in two variants: (i) monomorphic variant, presenting with the small macules or papules typically seen in adult patients; and (ii) polymorphic variant with larger lesions of variable size and shape, typically seen in children. The definition of polymorphic and monomorphic variants is mostly intuitive, and a validation of this classification has not been done.
M. Theiler,L. Weibel,S. Christen-Zaech,V. Carmignac,A. Sorlin,K. Neuhaus,M. Chevarin,C. Thauvin-Robinet,C. Philippe,L. Faivre,P. Vabres,P. Kuentz
doi : 10.1111/jdv.17319
Volume 35, Issue 10 p. 2085-2090
Postzygotic mutations in FGFR2 have been identified in mosaic forms of acne, keratinocytic epidermal nevi, nevoid acanthosis nigricans / rounded and velvety epidermal nevus and in two fetuses with papillomatous pedunculated sebaceous nevus (PPSN).
O. Zaar,S. Polesie,C. Navarrete-Dechent,E. Errichetti,B.N. Akay,J. Jaimes,H. Cabo,E. Cohen Sabban,J. Paoli
doi : 10.1111/jdv.17439
Volume 35, Issue 10 p. 2091-2096
The diagnosis of porokeratosis can be challenging, and knowledge about its dermoscopic features is limited.
A. Reimer-Taschenbrecker,M. Hess,A. Hotz,J. Fischer,L. Bruckner-Tuderman,C. Has
doi : 10.1111/jdv.17336
Volume 35, Issue 10 p. 2097-2104
Epidermolysis bullosa simplex (EBS) is the most common type of EB, a group of rare genodermatoses. Affected individuals suffer from skin blistering and report a high disease burden. In some EBS subtypes, plantar keratoderma (PK) has been described.
V. Piccolo,A. Bassi,G. Argenziano,C. Mazzatenta,M. Cutrone,I. Neri,R. Grimalt,T. Russo
doi : 10.1111/jdv.17409
Volume 35, Issue 10 p. e619-e620
I. Tessas,N. Kluger
doi : 10.1111/jdv.17422
Volume 35, Issue 10 p. e620-e622
D. Kadylak,W. Bara?ska-Rybak
doi : 10.1111/jdv.17424
Volume 35, Issue 10 p. e622-e624
A. Sánchez-Velázquez,A. Bauer-Alonso,T. Estrach,D. Vega-Díez,P. Garcia-Muret,L. Haya,Y. Peñate,E. Acebo,R. Fernández de Misa,M. Blanes,H.J. Suh-Oh,R. Izu,E. Silva-Díaz,J. Sarriugarte,C. Román-Curto,R. Botella-Estrada,A. Mateu-Puchades,L. Prieto-Torres,V. Morillas,M. Morillo,P. Sánchez-Caminero,L. Calzado,A. Pérez-Ferriols,A. Pérez,J.D. Domínguez,M. Navedo,C. Muniesa,A. Combalia,J. Arroyo-Andrés,M.A. Descalzo,I. García-Doval,P.L. Ortiz-Romero
doi : 10.1111/jdv.17430
Volume 35, Issue 10 p. e624-e626
P. K. Krajewski,J. C. Szepietowski
doi : 10.1111/jdv.17444
Volume 35, Issue 10 p. e626-e627
S.J. Park,H.S. Han,S.H. Shin,K.H. Yoo,K. Li,B.J. Kim,S.J. Seo,K.Y. Park
doi : 10.1111/jdv.17447
Volume 35, Issue 10 p. e628-e630
C. Lesort,J Kanitakis,L. Donzier,D. Jullien
doi : 10.1111/jdv.17451
Volume 35, Issue 10 p. e630-e632
P.K. Krajewski,?. Matusiak,J.C. Szepietowski
doi : 10.1111/jdv.17449
Volume 35, Issue 10 p. e632-e634
O.M. Orenay,I. Balta,D. Yigit,M. Eksioglu
doi : 10.1111/jdv.17454
Volume 35, Issue 10 p. e634-e635
S.K. Mahil,M. Yates,Z.Z.N. Yiu,S.M. Langan,T. Tsakok,N. Dand,K.J. Mason,H. McAteer,F. Meynell,B. Coker,A. Vincent,D. Urmston,A. Vesty,J. Kelly,C. Lancelot,L. Moorhead,H. Bachelez,F. Capon,C.R. Contreras,C. De La Cruz,P. Di Meglio,P. Gisondi,D. Jullien,J. Lambert,L. Naldi,S. Norton,L. Puig,P. Spuls,T. Torres,R.B. Warren,H. Waweru,J. Weinman,M.A. Brown,J.B. Galloway,C.M. Griffiths,J.N. Barker,C.H. Smith,the PsoProtect study group
doi : 10.1111/jdv.17450
Volume 35, Issue 10 p. e636-e640
R. Rrapi,S. Chand,J.A. Lo,C.K. Gabel,S. Song,Z. Holcomb,C. Iriarte,K. Moore,C.R. Shi,H. Song,F.D. Xia,D. Yanes,R. Gandhi,V.A. Triant,D. Kroshinsky
doi : 10.1111/jdv.17459
Volume 35, Issue 10 p. e640-e642
G. Martin-Ezquerra,P. Monreal,L. Mercuriali,E. Cañas-Ruano,R.M. Pujol,X. Duran,M. Masferrer Niubò,P. Domingo,J. Villar-Garcia,J. Lopez-Contreras,A. Gonzalez-Cordón,P. Garcia-Olalla,M.-J. Barberá,STI-HIV group of Barcelona
doi : 10.1111/jdv.17460
Volume 35, Issue 10 p. e642-e645
G. Damiani,A. Pacifico,F. Pelloni,M. Iorizzo
doi : 10.1111/jdv.17472
Volume 35, Issue 10 p. e645-e647
M.C. Alberelli,A. Panariello,M. Olivi,A. Borghi,P. Zedde,M. Corazza
doi : 10.1111/jdv.17463
Volume 35, Issue 10 p. e647-e649
F. Solimani,Y. Mansour,D. Didona,A. Dilling,K. Ghoreschi,K. Meier
doi : 10.1111/jdv.17480
Volume 35, Issue 10 p. e649-e651
N. Siliquini,M.T. Giura,R. Viola,S. Ribero,M. Panzone,P. Dapavo,M.T. Fierro,M. Ortoncelli,P. Quaglino
doi : 10.1111/jdv.17264
Volume 35, Issue 10 p. e651-e652
S. Tawil,C. Irani,R. Kfoury,S. Abramian,P. Salameh,K. Weller,M. Maurer,K. Ezzedine
doi : 10.1111/jdv.17277
Volume 35, Issue 10 p. e652-e654
L.K. Rangel,P. Adotama,P. Shah,K. Lo Sicco,A.N. Femia
doi : 10.1111/jdv.17288
Volume 35, Issue 10 p. e654-e656
A.-C. Garreau,J.-F. Stalder,S. Méry,P. Bunouf,C. Jean-Decoster,A. Nosbaum, on behalf of the Eczema Foundation, the French Group on Therapeutic Education in Dermatology (GET)
doi : 10.1111/jdv.17326
Volume 35, Issue 10 p. e656-e659
M. Kraft,J.M. Renaudin,L.F. Ensina,A. Kleinheinz,M.B. Bilò,K. Scherer Hofmeier,S. Dölle-Bierke,M. Worm
doi : 10.1111/jdv.17327
Volume 35, Issue 10 p. e659-e662
S. Wada,T. Namiki,S. Tokoro,K. Miura,H. Yokozeki
doi : 10.1111/jdv.17368
Volume 35, Issue 10 p. e662-e663
A. López-Valle,A. García-Reyne,C. Loinaz-Segurola,J. Sanchez-Pina,J.L. Rodríguez-Peralto,C. Zarco-Olivo
doi : 10.1111/jdv.17371
Volume 35, Issue 10 p. e663-e665
S. Idoudi,B. Bressac- de Paillerets,B. Balme,M.-N. Bonnet-Dupeyron,L. Golmard,L. Thomas
doi : 10.1111/jdv.17372
Volume 35, Issue 10 p. e665-e667
N. Gupta,C. Cullison,A. Mally,L. Xiang,S.T. Hill,M.G. Beveridge
doi : 10.1111/jdv.17373
Volume 35, Issue 10 p. e667-e670
L.M. Nieto-Benito,V. Parra-Blanco,Y. Gómez-Navarro,J. Menárguez-Palanca,A. Pulido-Pérez
doi : 10.1111/jdv.17375
Volume 35, Issue 10 p. e670-e672
C.C. Zouboulis,L.S. Shapiro,C.M. Magro
doi : 10.1111/jdv.17377
Volume 35, Issue 10 p. e672-e674
P.M. Ramos,D.F. Melo,L.R. Lemes,G. Alcantara,H.A. Miot,M.R. Lyra,T.J. de S. Vargas
doi : 10.1111/jdv.17379
Volume 35, Issue 10 p. e674-e676
D. Canu,J. Shourick,N. Andreu,A. Gey,F. Ballanger-Désolneux,H. Barailler,K. Boniface,K. Ezzedine,J. Seneschal
doi : 10.1111/jdv.17383
Volume 35, Issue 10 p. e676-e679
P. K. Can,A. Salman,S. Ho?gören-Tekin,E. Kocatürk
doi : 10.1111/jdv.17385
Volume 35, Issue 10 p. e679-e682
P. Nenoff,D. Koch,C. Krüger,C. Neumeister,M.R. Götz,U. Schwantes,R.-H. Bödeker,C. Borelli
doi : 10.1111/jdv.17386
Volume 35, Issue 10 p. e682-e684
C. De Simone,M. Mannino,P. Sollena,F. Deilhes,V. Sibaud,K. Peris
doi : 10.1111/jdv.17388
Volume 35, Issue 10 p. e684-e685
M. Mehta,A. O’Toole,M. Gooderham
doi : 10.1111/jdv.17410
Volume 35, Issue 10 p. e685-e688
A. Brugués,S. Ribero,A. Barreiro,S. Bassoli,A.P. García,C. Longo,S. Segura,L. Alós,J. Malvehy,S. Puig,C. Carrera
doi : 10.1111/jdv.17412
Volume 35, Issue 10 p. e688-e690
A. Sorlin,V. Carmignac,J. Amiel,O. Boccara,S. Fraitag,A. Maruani,M. Theiler,L. Weibel,Y. Duffourd,C. Philippe,C. Thauvin-Robinet,L. Faivre,J.-B. Rivière,P. Vabres,P. Kuentz
doi : 10.1111/jdv.17413
Volume 35, Issue 10 p. e690-e693
J. Young,S. Mizzi,L. Mercieca,M.J. Boffa
doi : 10.1111/jdv.17416
Volume 35, Issue 10 p. e693-e695
R. Happle,U. Wollina,S.B. Verma
doi : 10.1111/jdv.17417
Volume 35, Issue 10 p. e695-e697
A. Elyas,F. Dalgard,Å. Svensson
doi : 10.1111/jdv.17418
Volume 35, Issue 10 p. e697-e698
Do you want to add Medilib to your home screen?